Acura Pharmaceuticals receives second patent for Limitx
PALATINE - Acura Pharmaceuticals said it has received a U.S. patent for its Limitx Technology platform.
Limitx Technology is designed to address opioid abuse via the oral route of administration. Limitx contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested.
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary Limitx, Aversion and Impede technologies. Acura markets Nexafed and Nexafed Sinus, which are pseudoephedrine containing products that utilize the Impede Technology.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.